Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Method of treating tumors

Patent ·
OSTI ID:1175707
; ; ; ; ;
A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.
Research Organization:
The Regents of the University of California, Oakland, CA (United States); Merck Patent GmbH, Darmstadt (Germany)
Sponsoring Organization:
USDOE
DOE Contract Number:
FG01-00NE22944; FG03-84ER60233
Assignee:
The Regents of the University of California (Oakland, CA); Merck Patent GmbH (Darmstadt, DE)
Patent Number(s):
7,029,652
Application Number:
10/208,931
OSTI ID:
1175707
Country of Publication:
United States
Language:
English

References (3)

Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy journal February 2000
Synergy between an antiangiogenic integrin  v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases journal February 1999
Combined modality radioimmunotherapy: Promise and peril journal February 2002

Similar Records

Related Subjects

60 APPLIED LIFE SCIENCES